Front Page-Rx

Reining in Rx Drug Costs: What States Achieved in 2017 and Where They’re Heading in 2018

In a year of tense partisan debate over the future of health care, one issue has achieved rare bipartisan agreement — the need to curb rising prescription drug costs. Polls show again and again that Americans, regardless of political affiliation, view the high costs of drugs as one of their chief health care concerns. Reviews […]

Read More
  • Academy of Sciences Recommends Federal Strategies to Lower Rx Prices, But Some States Are Already Taking Action

    The National Academy of Sciences recently released a report recommending several strategies to curb prescription drug costs that attempt to strike a balance between reining in prices while fostering continued drug development and innovation. Several of the academy’s recommendations are already getting trial runs in states, which are experimenting with innovative cost-savings approaches in order […]

    Read More
  • Is It Safe and Cost-Effective to Import Drugs from Canada?

    Is It Safe and Cost-Effective to Import Drugs from Canada?

    States are considering importing prescription drugs from Canada, but is it safe? Will it save money? Can it be done? Three, easy-to-read infographics explain what state leaders need to know if they’re interested in drug importation legislation. 1. Is it safe to import drugs from Canada? Yes, 40 percent of all drugs sold in the […]

    Read More
  • Publications

    The Dormant Commerce Clause: What Impact Does It Have on the Regulation of Pharmaceutical Costs?

    When states pass laws designed to control prescription drug costs, the pharmaceutical industry often responds with lawsuits claiming states are hindering interstate commerce and violating the federal Dormant Commerce Clause (DCC). NASHP’s legal experts believe states can craft drug cost policies that can withstand industry challenges. This brief by Anna Zaret and Darien Shankse provides insight and […]

    Read More
  • State Health Policy Blog
    How States Can Avoid Dormant Commerce Clause Legal Challenges When Regulating Drug Costs

    How States Can Avoid Dormant Commerce Clause Legal Challenges When Regulating Drug Costs

    New state laws designed to control the costs of brand-name and generic prescription drugs often face legal challenges from the pharmaceutical industry. These lawsuits can vary depending on the individual state law, but recent industry lawsuits analyzed by the National Academy for State Health Policy (NASHP) share a common legal thread – drug manufacturers and […]

    Read More
  • State Health Policy Blog
    Utah’s Norman Thurston Takes a Red State Approach to Lower Rx Costs with a Bill to Import Drugs from Canada

    Utah’s Norman Thurston Takes a Red State Approach to Lower Rx Costs with a Bill to Import Drugs from Canada

    For more than a decade, Utah State Legislator and Director of the Office of Health Care Statistics Norman Thurston has worked to reform his state’s health care system, including its Medicaid program, and is considered one of the state’s “go-to” health care policymakers. Thurston, a Republican, has worked to reduce state spending on prescription drugs and […]

    Read More
  • An Interview with Drug Cost Control Advocate Richard Gottfried

    At NASHP’s 30th State Health Policy Conference, state leaders from legislative and executive branches across the nation gathered to talk about what they are doing to manage escalating prescription drug costs in their states. Several states have recently passed or proposed legislation to force more transparency in drug pricing or to try to regulate drug […]

    Read More
  • State Health Policy Blog

    Maryland Rate-Setting Legislation Question and Answer

    The National Academy for State Health Policy’s (NASHP) has crafted model legislation – called the Prescription Drug Rate-Setting Model Act – that states can use to regulate drug costs. The legislation creates a drug cost review commission that evaluates the affordability of certain drugs in the same way that states now regulate Medicaid, state employee […]

    Read More
    October 17, 2017 | Filed under: Blog Posts, Front Page, Front Page-Rx, State Health Policy Blog

  • State Health Policy Blog
    NASHP Awards Grants to Colorado, Delaware, and Oklahoma to Tackle Rising Rx Drug Prices

    NASHP Awards Grants to Colorado, Delaware, and Oklahoma to Tackle Rising Rx Drug Prices

    The National Academy for State Health Policy (NASHP) has awarded $300,000 in grants to Colorado, Delaware, and Oklahoma to help the states develop innovative policy solutions to tackle high prescription drug prices. With the support from the Laura and John Arnold Foundation, the funding enables states to explore promising policy approaches to control rapidly escalating […]

    Read More
  • State Health Policy Blog
    Lowering Drug Costs: Transparency Legislation Sets Off Flurry of New State Approaches

    Lowering Drug Costs: Transparency Legislation Sets Off Flurry of New State Approaches

    Responding to rapidly rising drug costs, 30 states across the country have drafted more than 60 drug price transparency bills designed to: Identify the costs that contribute to drug manufacturer expenses and list prices And unveil the often opaque business practices of pharmacy benefit managers (PBMs). In addition to promoting pricing transparency, as of early […]

    Read More